PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : G

Records returned : 85 (on 21 Nov 2024 at 16:34:51).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.07.03
04.07.04
04.08.01
Gabapentin
Pain (Neuropathic)
Green
Formulations :
  • Capsules
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
CD
NICE
Important
First line gabapentinoid.
04.07.03
04.07.04
04.08.01
Gabapentin
Restless Leg Syndrome
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Patients with severe sleep disturbance, RLS-related / co-morbid pain or history of impulse control disorder
04.07.03
04.07.04
04.08.01
Gabapentin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.07.03
04.07.04
04.08.01
Gabapentin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NFD1
NICE
04.07.03
04.07.04
04.08.01
Gabapentin
Pain
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
CD
Important
Not for chronic or acute, non-malignant pain. See separate formulary entry for use in neuropathic pain.
Gabapentin (Neuropathic Pain)
No Information Returned
04.11.00
Galantamine
Multiple sclerosis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.07.04
Galcanezumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Galsulfase
No Information Returned
Gamolenic acid
No Information Returned
05.03.02
11.03.03
Ganciclovir
Herpes infection
Green
Formulations :
  • Eye gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Preferred
05.03.02
11.03.03
Ganciclovir
Viral retinitis
Red
Formulations :
  • Intravitreal injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Consultant ophthalmologists only
05.03.02
11.03.03
Ganciclovir
Cytomegalovirus
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Ganirelix
No Information Returned
Gatifloxacin
No Information Returned
01.01.02
Gaviscon Advance
Gastro protection
Green
Formulations :
  • Chewable tablets
  • Suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.01.02
Gaviscon Infant
Gastro protection
Green
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Licensed up to 2 years of age
Gefitinib
No Information Returned
Gelatin
No Information Returned
Gemcitabine
No Information Returned
07.01.01
Gemeprost
Termination of pregnancy
Red
Formulations :
  • Pessaries
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Restricted to use by Gynaecology and Obstetrics departments only
02.12.00
Gemfibrozil
Lipid modification
Non Formulary
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Not for initiation in new patients.
05.01.04
11.03.01
13.10.01
Gentamicin sulfate
Bacterial infection
Red
Formulations :
  • Infusion
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Follow local guidelines on the use of antimicrobials. This drug requires therapeutic monitoring
05.01.04
11.03.01
13.10.01
Gentamicin sulfate
Bacterial keratitis / corneal ulcer
Red
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
1.5% preservative free eye drops (unlicensed)
05.01.04
11.03.01
13.10.01
Gentamicin sulfate
Bacterial eye infection
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
0.3% eye / ear drops
05.01.04
11.03.01
13.10.01
Gentamicin sulfate
Bacterial eye infection
Red
Formulations :
  • Subconjunctival injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Gentamicin 80mg/2ml ampoules
Gentian
No Information Returned
Gestonorone hexanoate
No Information Returned
Gestrinone
No Information Returned
Gilteritinib
No Information Returned
Glatiramer acetate
No Information Returned
05.03.03
Glecaprevir/pibrentasvir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
SA
NHSE
NICE
Glibenclamide
No Information Returned
Gliclazide
No Information Returned
Glimepiride
No Information Returned
Glipizide
No Information Returned
Gliquidone
No Information Returned
Glten free /wheat/free /low/protein cooking aids
No Information Returned
Glucagon
No Information Returned
09.12.00
Glucosamine
Osteoarthritis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Glucosamine hydrochloride (Rheumatic)
No Information Returned
Glucosamine sulfate (Rheumatic)
No Information Returned
Glucose
No Information Returned
Glucose and ketone blood testing reagents
No Information Returned
Glucose blood testing reagents
No Information Returned
Glucose/glycerol
No Information Returned
Glutaraldehyde
No Information Returned
Gluten free biscuits
No Information Returned
Gluten free breads
No Information Returned
Gluten free cakes/pastries
No Information Returned
Gluten free grains/flours
No Information Returned
Gluten free mixes
No Information Returned
Gluten free pastas
No Information Returned
Gluten free/low protein biscuits
No Information Returned
Gluten free/low protein bread
No Information Returned
Gluten free/low protein cereals
No Information Returned
Gluten free/low protein cooking aids
No Information Returned
Gluten free/low protein drink
No Information Returned
Gluten free/low protein grains/flours
No Information Returned
Gluten free/low protein mixes
No Information Returned
Gluten free/low protein pasta
No Information Returned
Gluten free/low protein sweet/savoury
No Information Returned
Gluten free/wheat free biscuits
No Information Returned
Gluten free/wheat free bread
No Information Returned
Gluten free/wheat free cakes/pastries
No Information Returned
Gluten free/wheat free cereals
No Information Returned
Gluten free/wheat free cooking aids
No Information Returned
Gluten free/wheat free grains/flours
No Information Returned
Gluten free/wheat free meals
No Information Returned
Gluten free/wheat free mixes
No Information Returned
Gluten free/wheat free pasta
No Information Returned
Gluten free/wheat free snacks
No Information Returned
Gluten free/wheat free/low protein biscuits
No Information Returned
Gluten free/wheat free/low protein mixes
No Information Returned
Gluten free/wheat free/low protein pasta
No Information Returned
01.06.02
11.08.02
Glycerol
Constipation
Green
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.07.04
02.06.01
Glyceryl trinitrate
Angina
Green
Formulations :
  • Sublingual tablets
  • Sublingual spray
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.07.04
02.06.01
Glyceryl trinitrate
Angina
Green
Formulations :
  • Patches
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.07.04
02.06.01
Glyceryl trinitrate
Anal fissures
Green (see narrative)
Formulations :
  • Ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
0.4% ointment is the 1st-line treatment option in adults. Use of unlicensed strengths / formulations is not supported.
01.07.04
02.06.01
Glyceryl trinitrate
Angina
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.07.04
02.06.01
Glyceryl trinitrate
Anal fissures
Non Formulary
Formulations :
  • Cream
  • Ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
U
Important
0.4% ointment is the 1st-line treatment option in adults. 0.1%, 0.2% and 2% creams and ointments are non-formulary
Glycopyrronium bromide
No Information Returned
Glycopyrronium/formoterol
No Information Returned
01.05.03
10.01.03
13.05.03
Golimumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ulcerative Colitis in Adults only. Prescribe by brand.
01.05.03
10.01.03
13.05.03
Golimumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.03
Golimumab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
01.05.03
10.01.03
13.05.03
Golimumab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.03
Golimumab
Non-radiographic axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.03
Golimumab
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
Gonadorelin
No Information Returned
06.07.02
08.03.04
Goserelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.07.02
08.03.04
Goserelin acetate
Transgender Health - adults
Amber
Formulations :
  • Implant
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
06.07.02
08.03.04
Goserelin acetate
Uterine fibroids
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
Granisetron
Nausea and vomiting (chemotherapy induced)
Non Formulary
Formulations :
  • Injection
  • Patches
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
Granisetron
Nausea and vomiting (post operative)
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Granisetron hydrochloride
No Information Returned
Gripe mixtures
No Information Returned
Griseofulvin
No Information Returned
Guaiacol and codeine
No Information Returned
Guaifenesin
No Information Returned
Guanethidine monosulfate
No Information Returned
04.04.00
Guanfacine
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Guanfacine hydrochloride
No Information Returned
Guar gum
No Information Returned
10.01.03
13.05.02
13.05.03
Guselkumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Guselkumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Guselkumab (Psoriasis)
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More